Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for drug-resistant epilepsy
IRCT20230813059134N1Phase 3Completed
- Sponsor
- Imam Neurology Research Center
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in epilepsy, sponsored by Imam Neurology Research Center. Started Mar 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
epilepsy
Beyond the preview
Go deeper on IRCT20230813059134N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230813059134N1.